No Data
No Data
Express News | Sonnet Biotherapeutics - Board Initiated Process to Explore and Review a Range of Strategic Alternatives Focused on Maximizing Stockholder Value
Express News | Sonnet Biotherapeutics Holdings Inc - Announces Review of Strategic Alternatives
Express News | Sonnet Biotherapeutics: Clinical Benefit Seen at 4 Months Post-Initiation of Dosing in 35% of Evaluable Patients (8/23) With Advanced Solid Tumors
Express News | Sonnet Biotherapeutics: Announces Updated Clinical Data for Son-1010 as Monotherapy/Combined With Anti-Pd-L1, With Increase in Dose-Escalation Target
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined With an Anti-PD-L1, Along With an Increase in the Dose-Escalation Target
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and
Sonnet BioTherapeutics Is Maintained at Buy by EF Hutton
Sonnet BioTherapeutics Is Maintained at Buy by EF Hutton
No Data